heavily on its price and its traded volume exceeded 6 million shares. As the average volume of RPC is 812 thousand, that’s quite a huge gain for the stock.RPC started to climb after the company announced target domestic and international commercialization of its Onko-Sure® cancer test and a research on the company by Goldman Small Cap. According to the latest news, now the corporation is optimistic on its future and expects higher profit. Apparently, after the negative price changes of the stock, the positive news has provoked traders.
Radient Pharmaceuticals Corporation is a vertically integrated pharmaceutical company, engaged in development, manufacture and marketing of medical diagnostic products. RPC has started this year with a low-trade, though in April the stock climbed up to $2.20 per share. However, since then the price has moved down. Last Friday, RPC closed the day at $0.83, though no one can predict how long the up move can resist.[BANNER]
The financial results of the company show that this year revenue and gross profit have increased, however, net loss of RPC got higher by 50%. Net income rose up significantly, as well as the total liabilities of the company, which still remain lower than its assets. In its financial report, RPC also states that it has entered into several distribution agreements.
Currently, the stock up move seems to be interrupted and RPC may need additional capital to cover its liabilities.
